Paris, France – April 22, 2026

In a landmark advancement for pediatric endocrinology, Sanofi has secured U.S. FDA approval to expand the use of Tzield (teplizumab-mzwv) for children as young as one year old diagnosed with stage 2 type 1 diabetes (T1D). This decision marks a critical milestone in disease-modifying therapy, positioning Tzield as the first and only treatment capable of delaying progression to stage 3 T1D in very young children, fundamentally shifting the paradigm of early diabetes intervention.

First Disease-Modifying Therapy for Early Pediatric T1D

The expanded approval of Tzield introduces a groundbreaking immunotherapy approach targeting the underlying autoimmune mechanisms of Type 1 Diabetes, rather than simply managing symptoms. Tzield works as a CD3-directed monoclonal antibody, modulating immune system activity to delay the destruction of insulin-producing beta cells in the pancreas.

This newly approved indication extends treatment eligibility from children aged eight years and older to those as young as one year, addressing a highly vulnerable population at elevated risk of rapid disease progression. Early intervention at this stage is critical, as stage 2 T1D is characterized by autoantibody presence and abnormal glucose levels, but without overt clinical symptoms.

By delaying progression to stage 3—where patients require lifelong insulin therapy—Tzield offers the potential to reduce disease burden during critical developmental years, improving both clinical outcomes and quality of life for patients and caregivers.

Advertisement

cGxPJobs Banner

Clinical Evidence Supporting Early Intervention

The FDA approval is supported by data from the Phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years of age. The study demonstrated that a 14-day intravenous treatment regimen was well tolerated and effective in delaying disease progression, reinforcing earlier findings in older populations.

Importantly, Tzield had previously received Breakthrough Therapy and Orphan Drug designations, underscoring its significant therapeutic potential in a rare and serious condition. The therapy has already been approved globally in multiple regions for patients aged eight years and older, and this expanded indication further strengthens its clinical utility across age groups.

Experts emphasize that autoimmune activity in T1D often begins early in life, making early immunomodulatory intervention essential. By targeting the immune system before extensive beta-cell destruction occurs, Tzield demonstrates the ability to alter the natural course of the disease, a long-sought goal in diabetes research.

Transforming the Future of Diabetes Management

The approval of Tzield for younger children represents a paradigm shift from reactive to proactive disease management in type 1 diabetes. Traditionally, treatment has focused on managing hyperglycemia after onset, but Tzield enables clinicians to intervene before clinical disease manifests, potentially delaying insulin dependence by years.

This innovation is particularly impactful given the progressive and lifelong nature of T1D, where patients experience increasing complications over time, including cardiovascular disease, neuropathy, and metabolic challenges. Delaying onset not only reduces immediate treatment burden but may also lower long-term healthcare costs and complications.

Sanofi continues to explore additional indications for Tzield, including use in patients recently diagnosed with stage 3 T1D, highlighting its broad therapeutic potential. As research advances, therapies like Tzield are expected to play a central role in precision medicine approaches targeting autoimmune diseases.

Overall, this approval reinforces Sanofi’s leadership in immunology and rare disease innovation, and signals a new era where early, targeted interventions can reshape chronic disease trajectories, offering hope to millions of families affected by type 1 diabetes worldwide.

Source: Sanofi press release